Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I, too, am curious. If the stock was trading at above $1 for the last 4 months, why give away 30% of the company for $22 million when the market potential is so large. Just doesn't add up. I'm not holding my breath and will wait it out, but if this is just standard procedure for Mr. Pernock, I'll be a lot less confident in his ability to lead this company.
Old very well said
May be they were hoping for good partnership and did not wanted to get a bad partnership and decided to dilute instead
I would just say wow
Amen rickk
The similarity should be obvious: both companies used a marketing pitch that a long-lasting, “semi-permanent” result was something to be desired. However, it turned out for both companies that robust demand for such semi-permanence never materialized.
In #msg-22443889, I pointed out that the docs trained by ARTE were performing 0.1 procedures per week, on average. I doubt that the docs trained by FCSC will do much better.
Actually, Artes Medical is not completely unrelated to FCSC—there are some eerie similarities. For instance, check out #msg-22443889; much of the content of this post could apply to FCSC is one merely changed the names.
#msg-22345733 has more of the same.
Excellent. good job Rickkk
Pricing is as follows: $2000 for the initial biopsy to send back the skin to the labs and grow the cells, they keep this specific for each patient and you could withdraw from your cells from anytime--she also did mention that if for some reason, your skin cells do not grow it is fully refundable
then its 700/injection from there
they said they would be offering it any day now. I believe the Maryland site was part of the clinical trials, so they do not need to be trained again, the doctors are ready to go
call yourself if you don't believe me 410-666-3960, she said alot of interest has been made
FCSC-definitely cheap , no doubt it.
Thanks for the advise!
Buy TEVA (and my favorite AIS).
OT: prescription drug to be replaced by generics.
http://www.healthnews.com/en/articles/09Zmrnpin0oQ15S69oAX3g/Prescription-Drug-Prices-Expected-to-Plummet-Due-to-Expiring-Patents/
Yes you are right but more likely scenario is poor shorts are stuck and need to cover it
this is from bloomberg.
http://www.bloomberg.com/news/2011-07-25/nasdaq-threshold-securities-for-july-22-table-.html?cmpid=yhoo
i went to sec website thrsold securities means 6. Mandatory Close-Outs of Threshold Securities.
Regulation SHO requires broker-dealers to close-out all failures to deliver that exist in threshold securities for thirteen consecutive settlement days by purchasing securities of like kind and quantity ("close-out").20
Until the position is closed out, the broker or dealer and any broker or dealer for which it clears transactions (for example, an introducing broker),21 may not effect further short sales in that threshold security without borrowing or entering into a bona fide agreement to borrow the security (known as a "pre-borrowing" requirement).
It means that shorts will have hard time covering it with profit and they will try to bring it down more so they can cover it with profitibility. correct me if i am wrong.
He won't do that prediction as he knows he will be wrong
Very well said atown
Can u please explain me why amrn jumped fro 65 cents to 19 dollars , what's the catalyst? There drug and potential for buyout or big partnership with upfront payments, right. They havenot even filed a nda yet. Fcsc has FDA approved personal cell therapy, they have spent 175 million for this approval. Can you explain this ridiculously low price. I guess it has same catalyst as amrn. Your thinking is flawed IMO. It's a big buy right now
Ha ha ha, good shot at skeptics.
You are not sounding like a basher at all! I understand the furstration. many have it on this board.
Sambrown communication, first of all great observation from your part on the grammer mistake. Yes they did the mistake. but you know, i dont think that makes fibrocell a bad company. Is GSK a bad company, GSk is also there client. Vicept a phase II company AGN just acquired , vicept was also there client. So this mistake for the sambrown does not makes FCSC a bad company at all.
Price action , i agree is the worst i have seen after FDA approval for any company. If you need money for short term , you are in trouble for sure. but if you can hold, like me, i think long term, it will be significantely higher than it is now. IMO. I may be wrong. we all are adults , and we pay for our mistakes. I am still confident on my investment in FCSC, for long term.
Good luck
I hate to sound like a 'basher' or whatever but if Sam Brown is such a great company for 'corporate communications' why would they make such a simple mistake on Fibrocell's blurb?? Please see: "Fibrocell Science Inc. is a biotechnology company focused on developing aesthetic, medical and scientific applications for regenerative fibroblast cells. Founded in 1995 as Isolagen, Inc., Fibrocell Science will continues to advance the scientific, medical and commercial potential of fibroblasts as ..."
The sentence structure or single word is incorrect. This is a COMMUNICATIONS company...making this mistake? The words should read simply "...will continue to advance..." OR "...Fibrocell Science continues to advance...".
I am one of the 'unwilling' investors at this point. I'm not happy with where this share price has tumbled too and I too am ticked that my money is stuck. I should have followed the 'rules' and pulled out at the 5% loss...but I didn't...I found myself listening to the optimism of the board and getting 'hooked'. Now I'm stuck...and I find myself just thinking...if I can give up on this $$...forget about it for a year or two...MAYBE I'll get a nice payday...however I am NOT convinced...and when I see something like I pointed out above on the Sam Brown WEBSITE...I'm MORE distressed and not happy. A communications company should be able to communicate effectively and professionally...the mistake I point out above...is 4th grade english. :(
I too find myself irritated by Dew but of all the posts here, his make the most sense. Sad but true. Everyone wants him to justify his statements and the funny thing is, if you read back into his postings from months ago, he has justified them I believe now he's just 'pestering' the board and having fun at everyone's expense. To me, that does not make sense since he has his own board and that should tell me that he wants people to be on his board and thereby increase his numbers, but with that in mind, why anger others and push away potential future board members??? I don't get that part. Oh well.
GLTA!
That was awesome . Sambrown Inc is great company with clients like gsk that's great. Behind the door fcsc is doing lot of good stuffs it seems.
Lol my English is not as good but my maths is!
LOL. DEW dont worry i wont loose my shirt. I am a physician and fcsc is less than 1 % of my assets. For you it might matter, but not for me! I know i will still not loose money in long term. If yopu are short you will, LOL!!
Would you bother to give calculation if you have one?. i dont need calculator to do calculations like you, as my arithmatics and mathematics are very powerful and yes i am arrogant. But what kind of idiot are you , even after asking so many times you dont bother to put your calculations on this board! every body has asked you , but instead to giving your logical thinking you try to bash it up and down .
Baby , try to influence some body else not me!!
Lannett news: Lannett Receives FDA Approval for Phentermine HCl Capsules, 37.5 mg.
Quote:
--------------------------------------------------------------------------------
Lannatte (LCI) news:
NEW YORK -- Broadfin Capital, LLC reported in an SEC filing that it owns 1,441,707 shares or 5.1 percent of the common stock of Lannett Company, Inc. (AMEX: LCI).
That more than doubles Broadfin's stake, which was 2.29 percent as of March 31, 2011. The firm's shares are worth $6.78 million at Lannett's Tuesday closing price of $4.70.
Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. The company is led Arthur Bedrosian, president and chief executive officer.
Broadfin is a New York hedge fund, founded by Kevin Kotler in 2005. He previously worked at Kevin's interest in medical technology goes back to his pre-med days at Furman Selz, UBS, ING, and The Galleon Group.
SEC filing: tinyurl.com/3l6po46
--------------------------------------------------------------------------------
Lannett news: Lannett Receives FDA Approval for Phentermine HCl Capsules, 37.5 mg.
Lannatte (LCI) news:
NEW YORK -- Broadfin Capital, LLC reported in an SEC filing that it owns 1,441,707 shares or 5.1 percent of the common stock of Lannett Company, Inc. (AMEX: LCI).
That more than doubles Broadfin's stake, which was 2.29 percent as of March 31, 2011. The firm's shares are worth $6.78 million at Lannett's Tuesday closing price of $4.70.
Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. The company is led Arthur Bedrosian, president and chief executive officer.
Broadfin is a New York hedge fund, founded by Kevin Kotler in 2005. He previously worked at Kevin's interest in medical technology goes back to his pre-med days at Furman Selz, UBS, ING, and The Galleon Group.
SEC filing: tinyurl.com/3l6po46
good observation for sure.
i think there were six positions before and six positions now. So no change IMO.
while the paint drys.... looks like two new positions have been added to the careers page.
i am not waiting for three weeks . i am not expecting huge event but what i know is that i am invested in a great company long term. Short term fluctuation in price does not matter.
What @#$$#@ facts are you trying to say, the link you sent is just price chart. we all know price has come down significantly. What are you trying to prove with that, can you explain? it,s a small biotech company with great potential and financing problem and stock is down, we all know that but the future potential is great. short term price fluctuations does not matter, and u need to understand that and get your facts straight. don,t behave like an idiot child. Just shut up and go to your hole!
Than go and sleep and stop bashing this stock up an down
Good article thanks, one more player who could be interested in fibrocell!
if they do some type of manufactering/partenership deal with GSK, man, that will be huge.
Lannatte (LCI) news:
NEW YORK -- Broadfin Capital, LLC reported in an SEC filing that it owns 1,441,707 shares or 5.1 percent of the common stock of Lannett Company, Inc. (AMEX: LCI).
That more than doubles Broadfin's stake, which was 2.29 percent as of March 31, 2011. The firm's shares are worth $6.78 million at Lannett's Tuesday closing price of $4.70.
Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. The company is led Arthur Bedrosian, president and chief executive officer.
Broadfin is a New York hedge fund, founded by Kevin Kotler in 2005. He previously worked at Kevin's interest in medical technology goes back to his pre-med days at Furman Selz, UBS, ING, and The Galleon Group.
SEC filing: http://tinyurl.com/3l6po46
Lannatte (LCI) news:
NEW YORK -- Broadfin Capital, LLC reported in an SEC filing that it owns 1,441,707 shares or 5.1 percent of the common stock of Lannett Company, Inc. (AMEX: LCI).
That more than doubles Broadfin's stake, which was 2.29 percent as of March 31, 2011. The firm's shares are worth $6.78 million at Lannett's Tuesday closing price of $4.70.
Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. The company is led Arthur Bedrosian, president and chief executive officer.
Broadfin is a New York hedge fund, founded by Kevin Kotler in 2005. He previously worked at Kevin's interest in medical technology goes back to his pre-med days at Furman Selz, UBS, ING, and The Galleon Group.
SEC filing: http://tinyurl.com/3l6po46
The parallels between Dendreon and Fibrocell are striking and IMO serve for better comparison. In the two years since approval DNDN has gone from $3 to over $30. We may not see our profit immediately but it will pay off to those of us who have patience.
Who cares what U say from day1 dew.
Many positives from article.
Another tool for doctors .
Cost of other fillers would be 3500 $ per year and it has to be done every 4 -6 months. Laviv, s effect exponentially increases rather than decrease like your favorite Botox . Definately a place on 10 plus billion market don't forget acne scar , burn and dental indication.
Dew keep thinking about it and take some sleeping pill and go to sleep.
I am glad , i made you laugh,, time will tell DEW..
This (not FCSC) is the kind of company AGN is interested in acquiring: